```

                     U.S. Securities and Exchange Commission
                             Washington, D.C. 20549

                                   FORM 10-QSB

[ ]     QUARTERLY  REPORT  UNDER  SECTION  13  OR  15(d)  OF  THE  SECURITIES
EXCHANGE  ACT  OF  1934  for  the  quarterly  period  ended  June  30,
2000.

[X ]     TRANSITION  REPORT  UNDER  SECTION  13  OR  15(d)  OF  THE  SECURITIES
EXCHANGE  ACT  OF  1934  for  the  transition  period  from  _______  to
_______

COMMISSION  FILE  NUMBER  001-06-560
                          ----------

                       FAIRCHILD INTERNATIONAL CORPORATION
                 (Name of Small Business Issuer in its Charter)

            Nevada                                         91-1880015
(State or other jurisdiction of             (IRS Employer Identification Number)
 Incorporation or Organization)

          Suite 600, 596 Hornby Street, Vancouver, B.C. Canada V6C 1A4
           (Address of Principal Executive Offices)         (Zip Code)

                                 (604) 646-5614
                           (Issuer's Telephone Number)

Check whether the issuer (1) filed all reports required to be filed by Section13
or  15(d)  of  the  Exchange  Act during the past 12 months (or for such shorter
period  that the registrant was required to file such reports), and (2) has been
subject  to  such  filing  requirements  for  the  past  90  days. Yes [x] No []

The  number  of  shares  of  common  stock  outstanding as of March 31, 2000 is
10,988,210.
-----------

ITEM  1.  FINANCIAL  INFORMATION

FAIRCHILD INTERNATIONAL CORPORATION
(A DEVELOPMENT STAGE COMPANY)

STATEMENT OF OPERATIONS AND DEFICIT

FOR THE THREE MONTHS ENDED MARCH 31, 2000 AND 1999

(EXPRESSED IN U.S. DOLLARS)

 	 	 	 	CUMULATIVE	PERIOD ENDED
 	 	 	 	TO	MARCH 31
 	 	 	 	MARCH 31
EXPENSES	 	 	2000	2000	1999

ADVERTISING	 	$	9,008	$	-	$	-
BANK CHARGES AND
  FOREIGN EXCHANGE	 	 	12,108	 	43	 	196
CONSULTING	 	 	 	39,267	 	-	 	664
OFFICE, RENT AND SECRETARIAL	 	25,040	 	5,884	 	5,380
PROFESSIONAL FEES 	 	 	78,183	 	1,728	 	-
PROMOTION AND TRAVEL	 	331,040	 	6,000	 	47,962
RELATED PARTY
  ADMINISTRATION CHARGES	 	119,855	 	10,733	 	5,000
  CONSULTING FEES	 	 	50,000	 	-	 	50,000
RESEARCH AND DEVELOPMENT AND
  LICENSE FEES	 	 	163,520	 	5,020	 	-
SHAREHOLDER INFORMATION	 	19,769	 	1,747	 	664
TELEPHONE AND UTILITIES	 	3,440	 	246	 	438
TRANSFER AGENT FEES	 	7,757	 	-	 	1,045

 	 	 	 	 	858,987	 	31,401	 	111,349

MINERAL INTEREST AND
    EXPLORATION COSTS	 	99,627	 	-	 	-

NET LOSS FOR THE PERIOD	 	958,614	 	31,401	 	111,349

DEFICIT BEGINNING OF THE PERIOD	 	 	 	927,213	 	456,276

DEFICIT END OF THE PERIOD	 	 	 	$958,614 	 	$567,625

BASIC LOSS PER SHARE

 	PRE STOCK SPLITS	 	 	 	 	$       0.01	 	$       0.01

 	POST STOCK SPLITS	 	 	 	$       0.01	 	$       0.03

UNAUDITED

FAIRCHILD INTERNATIONAL CORPORATION
(A DEVELOPMENT STAGE COMPANY)

BALANCE SHEET

MARCH 31, 2000

(EXPRESSED IN U.S. DOLLARS)

ASSETS	 	 	 	 	 	 	 	2000

    CURRENT
       CASH	 	 	 	 	 	 	$	5,186

LIABILITIES

    CURRENT
       ACCOUNTS PAYABLE	 	 	 	 	$	7,826
       OWING TO RELATED PARTIES	 	 	 	 	 	61,205

 	 	 	 	 	 	 	 	 	69,031
COMMITMENTS (NOTE 3)

STOCKHOLDERS' EQUITY

  SHARE CAPITAL
     AUTHORIZED
     50,000,000  COMMON SHARES WITH A PAR VALUE
                        OF $0.001 PER SHARE
      1,000,000   PREFERRED SHARES WITH A PAR VALUE
                        OF $0.01 PER SHARE
ISSUED AND FULLY PAID (NOTE 2)
    10,988,210 COMMON SHARES	 	 	 	 	 	894,769

DEFICIT ACCUMULATED DURING THE
  DEVELOPMENT STAGE	 	 	 	 	 	(958,614)

TOTAL STOCKHOLDERS' EQUITY	 	 	 	 	 	(63,845)

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	 	 	$	5,186

APPROVED BY THE DIRECTOR

UNAUDITED

FAIRCHILD INTERNATIONAL CORPORATION
(A DEVELOPMENT STAGE COMPANY)

STATEMENTS OF CASH FLOW

FOR THE THREE MONTHS ENDED MARCH 31, 2000 AND 1999

(EXPRESSED IN U.S. DOLLARS)

 	 	 	 	CUMULATIVE	PERIODS ENDED
 	 	 	 	TO	SEPTEMBER 30
 	 	 	 	MARCH 31
 	 	 	 	2000	2000	1999

CASH PROVIDED (USED) BY	 	 	$	-	$	-
    OPERATING ACTIVITIES

 	NET LOSS FOR THE PERIOD	$	(958,614)	$	(31,401)	$	(111,349)
 	NON-CASH ITEMS
 	ISSUE OF SHARES FOR SERVICES
           AND MINERAL INTEREST	 	236,858	 	-	 	-
 	CHANGE IN NON-CASH
 	  OPERATING ITEM
 	     ACCOUNTS PAYABLE	 	7,826	 	        (379)	 	(5,020)

 	 	 	 	 	(713,930)	 	(31,780)	 	(116,369)

FINANCING ACTIVITIES

 	OWING TO RELATED PARTIES	 	61,205	 	-	 	87,451
 	SHARE CAPITAL ISSUED FOR CASH	657,911	 	-	 	-
 	SHARE SUBSCRIPTIONS	 	-	 	-	 	30,000

 	 	 	 	 	719,116	 	-	 	117,451

CHANGE IN CASH FOR THE PERIOD	$	5,186	 	(31,780)	 	1,082

CASH BEGINNING OF THE PERIOD	 	 	 	36,966	 	595

CASH END OF THE PERIOD	 	 	$	5,186	$	1,677

UNAUDITED

FAIRCHILD INTERNATIONAL CORPORATION
(A DEVELOPMENT STAGE COMPANY)

NOTES TO THE FINANCIAL STATEMENTS

MARCH 31, 2000

1.	ACCOUNTING POLICIES AND NOTES

The accounting policies followed by the Company are unchanged from those outlined in the audited financial statements for the year ended December 31, 1999.  The notes to the financial statements at December 31, 1999 substantially apply to the interim
financial statements at March 31, 2000 and are not repeated here.  All adjustments have been made which, in the opinion of management, are necessary in order to make these financial statements not misleading.

2.	SHARE CAPITAL

         Common shares issued and fully paid                          SHARES	       CONSIDERATION

             Balance at March 31, 2000 and December 31, 1999        10,988,210	     $      894,769

3.	COMMITMENTS

a.	Pharmaceutical Research and Development

		The Company has entered into Research, Development and License Agreements to acquire an exclusive license to make, use and sell pharmaceutical products and processes relating to arthritis and dermal wrinkles.  The Company has paid $137,520 of the total
research and development funding obligation of $250,000 and issued 2,600,000 post-split common shares in consideration for the license.  The balance of the funding obligation is due by October 1, 2000.  The shares have been issued at a nominal value of
$.01 per share and are subject to regulatory restrictions relating to their saleability.  A net revenue royalty of 35% will be payable by the Company on revenue for licensed products.  The agreement is with a company formerly under common management.

b.	Consulting Agreement

		The Company entered into a consulting agreement with a former director for public relations services for a twelve month period to March 15, 2000.  As consideration for the services, the Company:

-	paid cash of $25,000;

-	issued 500,000 post-split (50,000 pre-split) shares at an ascribed value of $.50 per share;

			- granted options to acquire to March 15, 2000 (lapsed without being exercised) 500,000
			   post-split common shares at $.05 and 500,000 post-split common shares at $.15; and

			- granted an option to acquire up to 5% of the outstanding common shares of the Company when
			   these shares qualify for the NASDAQ small cap over the counter public trading at $.50 per
			   share for a period of two years from the date of the listing.

		As of March 31, 2000, the exercise price of outstanding stock options exceeded the quoted market value of the shares.  Accordingly, no stock option compensation has been recognized in the financial statements.

                                                     UNAUDITED

ITEM  2.PLAN  OF  OPERATION
With  the  exception of historical facts stated herein, the matters discussed in
this  report  are  "forward  looking"  statements  that  involve  risks  and
uncertainties  that  could  cause  actual  results  to  differ  materially  from
projected  results.  Such  "forward  looking"  statements  include,  but are not
necessarily  limited  to,  statements  regarding  anticipated  levels  of future
revenues and earnings from operations of the Company. Readers of this report are
cautioned  not to put undue reliance on "forward  looking" statements which are,
by  their  nature,  uncertain  as reliable indicators of future performance. The
Company  disclaims  any  intent  or obligation to publicly update these "forward
looking"  statements,  whether as a result of new information, future events, or
otherwise.

We  eventually  plan  to  develop  specialized e-commerce sites on the Internet.
Over  the  next  twelve  months,  we plan to focus on development of an Internet
portal  for alternative health care products.  We hope that this site will offer
our  products,  as  well  as  those of other companies.  In addition, we plan to
offer  information  on  related  topics  on  the  website.

In  the  past, we have relied upon funding from our former officer and director,
Mr.  David  Stadnyk.  We  borrowed  approximately  $44,000  from  Mr.  Stadnyk
during  our  development  stage,  $40,000  of  which  has  been  repaid.  We are
currently  unable  to  satisfy  our  cash  requirements  without  the  financial
support  of our President, Byron  Cox,  or  his  designee.  We  anticipate  that
we  will  meet  our  cash  requirements  for  the  next  twelve  months  through
Mr.  Cox's  financial support, even  though  Mr.  Cox  has  not  supplied  funds
to  the  Company  in  the  past.  Currently,  we  have no commitment for funding
from  our  past  or  present  officers  and  directors  or  any  other  party.

Eventually,  we will need to raise additional funds,  if we plan to implement an
advertising  and  marketing  plan  to  advance  our website.  We  have  not  yet
determined  how  we  plan  to  obtain  these  additional  funds.

In  1999,  we raised cash proceeds of $475,000 from the sale of our common stock
to business associates and friends of Mr. Standyk and Mr. Cox.  These funds were
for  general  operating expenses.  At the time these funds were raised they were
not intended for the Praxis Pharmaceuticals licensing agreement. In this regard,
we  issued  3,000,000  shares  for  $150,000  on  March  15,  1999 and we issued
1,000,000 shares on April 1, 1999 for $300,000.   The proceeds are to be used to
implement  our new plan of business.  At the time of sale, the proceeds were not
earmarked  for  the  Praxis  Pharmaceuticals  licensing  agreement.

Since we have entered into an agreement with Praxis Pharmaceuticals for research
and development, we will encounter significant research and development expenses
over  the  next  twelve  months.  In  addition  to  the  terms  of  the  Praxis
Pharmaceuticals  agreement,  we  may  seek  to  conduct  other  research  and
development,  which  would  result  in  expenses  beyond  those  outlined in the
agreement  with  Praxis  Pharmaceuticals.

Our  goal  is  to  have Praxis Pharmaceuticals provide us with products that are
ready  for  market.  The  first  product  that  we  hope  to receive from Praxis
Pharmaceuticals  is  the  anti-wrinkle compound while the second is an arthritis
product.

Since we outsource most of our operations, we do not anticipate establishing our
own  manufacturing  facilities  over  the  next twelve months.  Beyond this time
frame,  we  plan to make a decision with regard to purchase or sale of any plant
and  significant equipment in the long term after products are introduced to the
public  through  our  website,  if  ever.  As  conditions  dictate,  we  will
engage  additional employees.  We do not plan to make  any  significant  changes
in  the  number  of  employees  over  the  next  twelve  months.

Item  3.  Defaults  Upon  Senior  Securities
None.

Item  4.  Submission  of  Matters  to  a  Vote  of  Security  Holders
None.

Item  5.  Other  Information
None.

Item  6.  Exhibits  and  Reports  on  Form  8-K
None.

SIGNATURES

In  accordance  with  the  requirements  of  the  Securities  Exchange  Act
of  1934,  the  registrant  has  duly  caused  this  report  to  be  signed  on
its  behalf  by  the  undersigned,  thereunto  duly  authorized.

Dated:  8/24/00                       By:  /s/  Byron  Cox
                                      ---------------------
                                      Byron  Cox,  President  and  Director

<DOCUMENT>
<TYPE>     EX-27
<DESCRIPTION>     FINANCIAL DATA SCHEDULE
<ARTICLE> 5
<LEGEND>
     replace this with text
</LEGEND>
<MULTIPLIER> 1000

<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>               December 31, 2000
<PERIOD-START>                  January 1, 2000
<PERIOD-END>                    March 31, 2000
<CASH>                             5,186
<SECURITIES>                           0
<RECEIVABLES>                          0
<ALLOWANCES>                           0
<INVENTORY>                            0
<CURRENT-ASSETS>                   5,186
<PP&E>                                 0
<DEPRECIATION>                         0
<TOTAL-ASSETS>                     5,186
<CURRENT-LIABILITIES>             69,031
<BONDS>                                0
<PREFERRED-MANDATORY>                  0
<PREFERRED>                            0
<COMMON>                         894,794
<OTHER-SE>                             0
<TOTAL-LIABILITY-AND-EQUITY>     (63,845)
<SALES>                                0
<TOTAL-REVENUES>                       0
<CGS>                                  0
<TOTAL-COSTS>                          0
<OTHER-EXPENSES>                  31,401
<LOSS-PROVISION>                       0
<INTEREST-EXPENSE>                     0
<INCOME-PRETAX>                  (31,401)
<INCOME-TAX>                           0
<INCOME-CONTINUING>              (31,401)
<DISCONTINUED>                         0
<EXTRAORDINARY>                        0
<CHANGES>                              0
<NET-INCOME>                     (31,401)
<EPS-PRIMARY>                      (0.01)
<EPS-DILUTED>                      (0.01)
```